Setrobuvir
Подписчиков: 0, рейтинг: 0
|
| |
| Names | |
|---|---|
|
Preferred IUPAC name
N-(3-{(4aR,5S,8R,8aS)-1-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl}-1,1-dioxo-1,4-dihydro-1λ6,2,4-benzothiadiazin-7-yl)methanesulfonamide | |
| Other names
ANA-598; ANA598
| |
| Identifiers | |
|
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider |
|
| KEGG |
|
|
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C25H25FN4O6S2 | |
| Molar mass | 560.62 g·mol−1 |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Setrobuvir (also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C that was discovered at Anadys Pharmaceuticals, which was acquired by Roche in 2011; Roche terminated development in July 2015. It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1.
Setrobuvir works by inhibiting the hepatitis C enzyme NS5B, an RNA polymerase.
| Hepatitis C |
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis D | |||||||||
| Picornavirus | |||||||||
| Anti-influenza agents | |||||||||
| Multiple/general |
|
||||||||
| |||||||||